Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208
4136 Background: Mesothelin (MSLN) is overexpressed in 80-85% of pancreatic adenocarcinomas (PDAC). Anetumab ravtansine (AR) is a fully human anti-MSLN immunoglobulin G1 antibody conjugated to the anti-tubulin maytansinoid DM4. Through NCI-ETCTN, the North American Star Consortium conducted a phase...
Saved in:
Published in | Journal of clinical oncology Vol. 40; no. 16_suppl; p. 4136 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.06.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | 4136
Background: Mesothelin (MSLN) is overexpressed in 80-85% of pancreatic adenocarcinomas (PDAC). Anetumab ravtansine (AR) is a fully human anti-MSLN immunoglobulin G1 antibody conjugated to the anti-tubulin maytansinoid DM4. Through NCI-ETCTN, the North American Star Consortium conducted a phase I study to evaluate the safety/tolerability of AR in various combinations in patients (pts) with PDAC. Here, we report preliminary results of the escalation part. Methods: Pts with advanced PDAC after at least one line of treatment were included. AR was combined with nivolumab (ARM1), nivolumab/ipilimumab (ARM 2), or nivolumab plus gemcitabine (Gem) (ARM3), using an integrated biomarker analysis. Two dose levels (DL) of AR were evaluated, DL1=5.5mg/kg and DL2=6.5mg/kg (established RP2D). Key eligibility criterion was MSLN expression in >5% of tumor cells by immunohistochemistry. Pts with prior anti-PD1/anti-CTLA4 treatment were excluded but treatment with prior Gem was allowed. Mandatory blood and paired tumor samples were collected for investigation of the immune microenvironment, genomic/transcriptomic changes and for an in-depth description of AR pharmacokinetics. Results: Data cut-off date was 22/01/2022. A total of n=33 pts were enrolled, n=11 (ARM 1), n=13 (ARM 2) and n=9 (ARM3). Median age of pts was 66 (40-83), 33% of PS=0 and 66% of PS=1. Twenty-six pts (79%) had previously been exposed to Gem. Median number of prior lines of treatment was 3 (1-7). Twenty-eight patients were evaluable for DLT. Grade (G)3/4 TRAEs: 0% in ARM1DL1, 5.3% in ARM1DL2, 0% in ARM2DL1, 16.9% in ARM2DL2, 8.6% in ARM3DL1 and 19.5% in ARM3DL2. There were 2 dose-limiting toxicities in ARM2DL2, one G3 upper gastrointestinal haemorrhage, possibly related to AR, and one G3 thrombocytopenia and G3 anaemia, definitely related to AR. Ocular toxicity events were G1/2 blurred vision in 5/33 (15%) and G1 xerophthalmia in 1/33 (3%), related to both AR and anti-PD1; G2 keratitis in 1/33 (3%), related to AR only. Only G1 peripheral neuropathy was observed in 4/33 (12%) pts. Efficacy data is presented in the table. In ARM3, the range of tumor measurement (ΤΜ) change was Δ
TM
=–16.8% to +16.2% and 3/8 (36%) pts with SD had previously been exposed to Gem. Conclusions: Based on the observed disease control rate and acceptable toleratbility, ARM3 (both DL1 and DL2) will be tested in the expansion part. A further 20 patients will be recruited for dose confirmation and comprehensive biomarker evaluation. Pharmacokinetic/pharmacodynamic analysis is under way. Clinical trial information: NCT03816358. [Table: see text] |
---|---|
AbstractList | 4136
Background: Mesothelin (MSLN) is overexpressed in 80-85% of pancreatic adenocarcinomas (PDAC). Anetumab ravtansine (AR) is a fully human anti-MSLN immunoglobulin G1 antibody conjugated to the anti-tubulin maytansinoid DM4. Through NCI-ETCTN, the North American Star Consortium conducted a phase I study to evaluate the safety/tolerability of AR in various combinations in patients (pts) with PDAC. Here, we report preliminary results of the escalation part. Methods: Pts with advanced PDAC after at least one line of treatment were included. AR was combined with nivolumab (ARM1), nivolumab/ipilimumab (ARM 2), or nivolumab plus gemcitabine (Gem) (ARM3), using an integrated biomarker analysis. Two dose levels (DL) of AR were evaluated, DL1=5.5mg/kg and DL2=6.5mg/kg (established RP2D). Key eligibility criterion was MSLN expression in >5% of tumor cells by immunohistochemistry. Pts with prior anti-PD1/anti-CTLA4 treatment were excluded but treatment with prior Gem was allowed. Mandatory blood and paired tumor samples were collected for investigation of the immune microenvironment, genomic/transcriptomic changes and for an in-depth description of AR pharmacokinetics. Results: Data cut-off date was 22/01/2022. A total of n=33 pts were enrolled, n=11 (ARM 1), n=13 (ARM 2) and n=9 (ARM3). Median age of pts was 66 (40-83), 33% of PS=0 and 66% of PS=1. Twenty-six pts (79%) had previously been exposed to Gem. Median number of prior lines of treatment was 3 (1-7). Twenty-eight patients were evaluable for DLT. Grade (G)3/4 TRAEs: 0% in ARM1DL1, 5.3% in ARM1DL2, 0% in ARM2DL1, 16.9% in ARM2DL2, 8.6% in ARM3DL1 and 19.5% in ARM3DL2. There were 2 dose-limiting toxicities in ARM2DL2, one G3 upper gastrointestinal haemorrhage, possibly related to AR, and one G3 thrombocytopenia and G3 anaemia, definitely related to AR. Ocular toxicity events were G1/2 blurred vision in 5/33 (15%) and G1 xerophthalmia in 1/33 (3%), related to both AR and anti-PD1; G2 keratitis in 1/33 (3%), related to AR only. Only G1 peripheral neuropathy was observed in 4/33 (12%) pts. Efficacy data is presented in the table. In ARM3, the range of tumor measurement (ΤΜ) change was Δ
TM
=–16.8% to +16.2% and 3/8 (36%) pts with SD had previously been exposed to Gem. Conclusions: Based on the observed disease control rate and acceptable toleratbility, ARM3 (both DL1 and DL2) will be tested in the expansion part. A further 20 patients will be recruited for dose confirmation and comprehensive biomarker evaluation. Pharmacokinetic/pharmacodynamic analysis is under way. Clinical trial information: NCT03816358. [Table: see text] |
Author | Spreafico, Anna Dayyani, Farshid Abushahin, Laith I. Smaglo, Brandon George Kim, Edward Siu, Lillian L. Gbolahan, Olumide B. Patel, Reema Anil Lenz, Heinz-Josef Kalyan, Aparna Ezenwajiaku, Nkiruka Oberstein, Paul Eliezer Kasi, Anup Spiliopoulou, Pavlina Al Hallak, Mohammed Najeeb Amin, Manik A. Messersmith, Wells A. Cardin, Dana Backlund Paluri, Ravi Kumar Moscow, Jeffrey |
Author_xml | – sequence: 1 givenname: Pavlina surname: Spiliopoulou fullname: Spiliopoulou, Pavlina organization: Princess Margaret Cancer Centre, Toronto, ON, Canada – sequence: 2 givenname: Anup surname: Kasi fullname: Kasi, Anup organization: University of Kansas Cancer Center, Westwood, KS – sequence: 3 givenname: Laith I. surname: Abushahin fullname: Abushahin, Laith I. organization: The Ohio State University, Comprehensive Cancer Center, Columbus, OH – sequence: 4 givenname: Dana Backlund surname: Cardin fullname: Cardin, Dana Backlund organization: Vanderbilt-Ingram Cancer Center, Nashville, TN – sequence: 5 givenname: Heinz-Josef surname: Lenz fullname: Lenz, Heinz-Josef organization: USC Norris Comprehensive Cancer Center, Los Angeles, CA – sequence: 6 givenname: Farshid surname: Dayyani fullname: Dayyani, Farshid organization: UC Irvine Health, Orange, CA – sequence: 7 givenname: Wells A. surname: Messersmith fullname: Messersmith, Wells A. organization: University of Colorado Comprehensive Cancer Center, Aurora, CO – sequence: 8 givenname: Nkiruka surname: Ezenwajiaku fullname: Ezenwajiaku, Nkiruka organization: University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL – sequence: 9 givenname: Paul Eliezer surname: Oberstein fullname: Oberstein, Paul Eliezer organization: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY – sequence: 10 givenname: Ravi Kumar surname: Paluri fullname: Paluri, Ravi Kumar organization: Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC – sequence: 11 givenname: Reema Anil surname: Patel fullname: Patel, Reema Anil organization: Markey Cancer Center, University of Kentucky, Lexington, KY – sequence: 12 givenname: Edward surname: Kim fullname: Kim, Edward organization: Department of Medicine, Division of Hematology and Oncology, University of California at Davis, Sacramento, CA – sequence: 13 givenname: Aparna surname: Kalyan fullname: Kalyan, Aparna organization: Northwestern University, Chicago, IL – sequence: 14 givenname: Brandon George surname: Smaglo fullname: Smaglo, Brandon George organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 15 givenname: Manik A. surname: Amin fullname: Amin, Manik A. organization: Dartmouth-Hitchcock Medical Center, Lebanon, NH – sequence: 16 givenname: Mohammed Najeeb surname: Al Hallak fullname: Al Hallak, Mohammed Najeeb organization: Karmanos Cancer Institute, Wayne State University, Detroit, MI – sequence: 17 givenname: Olumide B. surname: Gbolahan fullname: Gbolahan, Olumide B. organization: University of Alabama at Birmingham, Birmingham, AL – sequence: 18 givenname: Lillian L. surname: Siu fullname: Siu, Lillian L. organization: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada – sequence: 19 givenname: Jeffrey surname: Moscow fullname: Moscow, Jeffrey organization: National Cancer Institute, Rockville, MD – sequence: 20 givenname: Anna surname: Spreafico fullname: Spreafico, Anna organization: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada |
BookMark | eNpdkEtOwzAQQC1UJNrCHcwBUsafOCk7VPEpqigLkNhFY9dVjRonspOiXooz4oiKBauZefOT3oSMfOMtIdcMZowD3Dwv1jMOnM9kAqqKfdvuZ5IJdUbGLOdFVhR5PiJjKATPWCk-Lsgkxk8AJkuRj8n36w6jpUtNY9dvjrTZUvS262vUNOChQx_dwVLnqWlq7Tx2rvH0y3U76uq69023swHbtBj-gXbfR2p2tv4j6Uht41Dunc-sDy61NxQ3B_QmJW0KwaYPJjHrG4PBON_UeEtfFksGHMpLcr7FfbRXpzgl7w_3b4unbLV-XC7uVplhoFRWsHKuuOFcWcZLyJVUAgWoAtBiLjSKNGH4nOd5WWhWSAZCb6U2WhspAcSUzH_vmtDEGOy2aoOrMRwrBtUgvkriq0F8JRM4ia8G8eIHfHN-ww |
CitedBy_id | crossref_primary_10_1186_s13046_023_02868_x crossref_primary_10_1016_j_ejphar_2024_176451 crossref_primary_10_3389_fimmu_2024_1287459 crossref_primary_10_1007_s11912_023_01367_8 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/JCO.2022.40.16_suppl.4136 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 4136 |
ExternalDocumentID | 10_1200_JCO_2022_40_16_suppl_4136 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 IPNFZ K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RIG RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-LOGICAL-c1066-718962c226e128056463a30670aea53ba3718c2925587b174103bf4bcbbc44003 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 01:53:39 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1066-718962c226e128056463a30670aea53ba3718c2925587b174103bf4bcbbc44003 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_JCO_2022_40_16_suppl_4136 |
PublicationCentury | 2000 |
PublicationDate | 2022-06-01 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2022 |
SSID | ssj0014835 |
Score | 2.4428868 |
Snippet | 4136
Background: Mesothelin (MSLN) is overexpressed in 80-85% of pancreatic adenocarcinomas (PDAC). Anetumab ravtansine (AR) is a fully human anti-MSLN... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 4136 |
Title | Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2IU28TDBA3GUktJcuYXHcpOENKmBFbKtEJ_Utsl1XjWidqmkmlR_Fb-T4kkvHJmAvUXOUHjk6X87FPheE3k6n0yCcSOoxQqVHdRPMniAQqkDwzCQEJNL06T47j04v6ddxd7yze9DKWirX3Bc_b6wruYtUgQZy1VWy_yHZmikQ4DfIF64gYbj-k4yHM7BBnQG3TWLNkb6S63LBeGfFrsDtM7npNtMcImAra7PzmumyEFd8tTE56VuE5bwsOiDORU0BJgtZ6FvwSz1YkE4hnTQpBKBUrP8pgCYVWMiVyFS-MKN_zvuDQI_pvMUTrqszcyW2dvm_L7N5li_zcp6X1t29mrtx38ZIsCKzSZlu-8wcY5XFjM1sZ4RvTL_rwG8OWuBzUK6ynnU-MvFjXqpJe-cDguY6Q8spyDgkHqiksbVlToGTGCIG2_q30vC2IVSF5Cgt9MDUltYGQx61PIDq9g_rQuzg7P6Fr5fjUyA5Zn7Dot3R-5qlrfMfdeRF9DFi_yLVrFIKBMcq1ax20T0SJ12do_plXOcsQehqJ8ZWL76P3rh1vbt1VS2Hq-U5jR6gAydo_MHi9yHakeoQ7Z-5pI5DdDS07dM3x3jUVAMWx_gID5vG6ptH6JfBOx5wbPCO8ymu8I4bvONM4RbescY73oI3zlfXCBrvuI13zeQGvOMK77jBO97G-3tcof0xuvz8adQ_9dy8EU8E4Hl74KYlEREQkEjw2iAyoFHIdEh9wiTrhpyF8IQgCUThvZhDKB-chHxKueBcULCF4RO0p3IlnyIciyRkgSQkiXu6QRMDf4R3qexOGO0lE_YMkUoo6dK2lUn_Cornd_nTC3S_-XZeor31qpSvwI9e89cGW78BXxTODA |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+Ib+study+of+anetumab+ravtansive+in+combination+with+immunotherapy+or+immunotherapy+plus+chemotherapy+in+mesothelin-enriched+advanced+pancreatic+adenocarcinoma%3A+NCI10208&rft.jtitle=Journal+of+clinical+oncology&rft.au=Spiliopoulou%2C+Pavlina&rft.au=Kasi%2C+Anup&rft.au=Abushahin%2C+Laith+I.&rft.au=Cardin%2C+Dana+Backlund&rft.date=2022-06-01&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=40&rft.issue=16_suppl&rft.spage=4136&rft.epage=4136&rft_id=info:doi/10.1200%2FJCO.2022.40.16_suppl.4136&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2022_40_16_suppl_4136 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |